Overview

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-11-15
Target enrollment:
Participant gender:
Summary
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
Phase:
PHASE3
Details
Lead Sponsor:
Viridian Therapeutics, Inc.